At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable. The William Harvey Research Institute (WHRI) was founded in 1986 by Nobel Laureate Sir John Vane, whose ground-breaking work on the mechanisms of action of aspirin fathered research into the role lipids play during inflammation. Since 1986, the WHRI has grown to become one of the largest pharmacological institutes in Europe, with over 530 clinicians and scientists from 45 countries, offering a multidisciplinary scientific environment devoted to therapeutic innovation in cardiovascular, inflammatory and endocrine diseases. Our major strength is in bringing together talented scientists with diverse skills, combining disciplines such as cell biology, bioengineering, epidemiology, genomics, immunobiology and pharmacology leading to clinical trials all with the aim of therapeutic innovation. Our international research environment is made particularly rich through successful and close collaboration with Barts Health NHS Trust, Genomics England and the 100,000 Genomes Project but also from links that further afield with international pharma and biotech companies. This diversity of collaboration enriches our research environment but also provides our students with first-hand experience of the power of cross-disciplinary working. By providing the highest calibre training and education in a diverse and cutting-edge research environment, the WHRI delivers therapeutic innovation hand-in-hand with developing the next generation of scientists to become the research leaders of tomorrow.